Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4784.30% year-on-year.
Undervalued
The company’s latest PE is -2.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 114.13M shares, increasing 37.39% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.85M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.12.